Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AERAS-404 Boost after BCG Prime
NCT02420444Phase 1Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Jan 2011
- Primary completion
- May 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of H4:IC31 in Tuberculosis (TB) (3 arms), sponsored by Aeras Global Vaccine Foundation. Primary endpoint: Number of unsolicited, solicited, and serious adverse events (SAEs) at 259 days. Started Jan 2011; status: completed.
02
Drugs
H4:IC31
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02420444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420444.